Camrelizumab combined with tegafur gimeracil oteracil potassium (S-1) and nab-paclitaxel for the treatment of initially unresectable cholangiocarcinoma
10.3760/cma.j.cn112152-20250116-00023
- VernacularTitle:卡瑞利珠单抗联合替吉奥和白蛋白紫杉醇治疗初始不可切除胆管癌
- Author:
Xiaofeng LIAO
1
;
Wangjie ZHAO
;
Hao HU
;
Yuan ZHU
;
Wei GONG
;
Xiaogang LI
Author Information
1. 武汉科技大学襄阳市中心医院研究生培养基地，襄阳441021
- Publication Type:Journal Article
- Keywords:
Cholangiocarcinoma;
Camrelizumab;
Tegafur gimeracil oteracil potassium (S-1);
Albumin-bound paclitaxel;
Efficacy;
Untoward reaction
- From:
Chinese Journal of Oncology
2025;47(11):1126-1131
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the safety and efficacy of camrelizumab combined with tegafur gimeracil oteracil potassium (S-1) and albumin-bound paclitaxel in the treatment of initially unresectable cholangiocarcinoma.Methods:From October 2022 to August 2024, 17 patients with unresectable intrahepatic cholangiocarcinoma and 4 patients with hilar cholangiocarcinoma were admitted to Xiangyang Central Hospital. They received treatment with camrelizumab combined with S-1 and nab-paclitaxel. Their short-term efficacy and adverse reactions were evaluated, and their long-term survival was followed up.Results:Of the 21 patients, 2 were in complete remission, 6 were in partial remission, 12 had stable disease, and 1 had progressive disease. The objective remission rate was 38.10% (8/21), and the disease control rate was 95.23% (20/21). Five patients were converted to resectable cholangiocarcinoma, with a conversion success rate of 23.81%,2 patients had complete postoperative pathological remission, and 3 patients had major pathological remission. The median progression-free survival time was 11 months (95% CI: 8.37-13.62), and the 1-year progression-free and overall survival rates were 28.57% and 95.23%, respectively. The overall adverse event rate was 90.48% (19/21), and the grade 3 adverse event rate was 28.57% (6/21). Conclusion:The combination of camrelizumab with S-1 and nab-paclitaxel for initially unresectable cholangiocarcinoma has favorable short-term efficacy, tolerable adverse reactions, and improved long-term survival for patients.
